153172-33-9

Basic information

• Product Name: 4H-1,3-Dioxolo4,5-cpyrrole, 4-(1,1-dimethylethyl)dimethylsilyloxymethyl-3a,6a-dihydro-2,2-dimethyl-, (3aR,4R,6aS)-
• Synonyms: 4H-1,3-Dioxolo4,5-cpyrrole, 4-(1,1-dimethylethyl)dimethylsilyloxymethyl-3a,6a-dihydro-2,2-dimethyl-, (3aR,4R,6aS)-;5-O-tert-butyldiMethylsilyl-1,N-dehydro-1,4-dideoxy-1,4-iMino-2,3-O-isopropylidene-D-ribitol, 5-O-tert-butyldiMethylsilyl-1,N-dehydro-1,4-dideoxy-1,4-iMino-2,3-O-iso-propylidene-D-ribitol;(3aR,4R,6aS)-4-[[[(1,1-Dimethylethyl)dimethylsilyl]oxy]methyl]-3a,6a-dihydro-2,2-dimethyl-4H-1,3-dioxolo[4,5-c]pyrrole;5-O-tert-Butyldimethylsilyl-1,N-dehydro-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol
• CAS NO: 153172-33-9
• Molecular Formula: C₁₄H₂₇NO₃Si
• Molecular Weight: 285.45458
• Mol File: 153172-33-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4H-1,3-Dioxolo4,5-cpyrrole, 4-(1,1-dimethylethyl)dimethylsilyloxymethyl-3a,6a-dihydro-2,2-dimethyl-, (3aR,4R,6aS)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1,3-Dioxolo4,5-cpyrrole, 4-(1,1-dimethylethyl)dimethylsilyloxymethyl-3a,6a-dihydro-2,2-dimethyl-, (3aR,4R,6aS)-(153172-33-9)
• EPA Substance Registry System: 4H-1,3-Dioxolo4,5-cpyrrole, 4-(1,1-dimethylethyl)dimethylsilyloxymethyl-3a,6a-dihydro-2,2-dimethyl-, (3aR,4R,6aS)-(153172-33-9)

Safety Data

• Hazardous Substances Data: 153172-33-9(Hazardous Substances Data)

Upstream product

• 30725-00-9 2,3-O-isopropylidene-D-ribonic-γ-lactone 
• 5336-08-3 D-Ribono-1,4-lactone 
• 532-20-7 D-Ribose 
• 1044813-00-4 5-O-tert-butyldimethylsilyl-2,3-O-isopropylidene-L-lyxonic acid-1,4-lactone 
• 152006-17-2 2,3-O-isopropylidene-L-lyxono-1,4-lactone 
• 89747-54-6 (3R,4R,5R)-4,5-dihydro-3,4-(O,O)-isopropylidene-5-mesyloxymethyl-2-(3H)-furanone 
• 153172-30-6 1-amino-1,4-anhydro-N-benzyl-5-O-tertbutyldimethylsilyl-1-deoxy-2,3-O-isopropylidene-D-ribitol 
• 117858-84-1 N-benzyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 153172-31-7 (3aR,4R,6aS)-4-({[(tert-butyl)(dimethyl)silyl]oxy}methyl)tetrahydro-2,2-dimethyl-3aH-[1,3]dioxolo[4,5-c]pyrrole 
• 153172-32-8 (3aR,4R,6aS)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-5-chloro-2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyrrole 

Downstream Products

• 153172-36-2 (3aR,4R,6S,6aS)-4-(tert-Butyl-dimethyl-silanyloxymethyl)-2,2-dimethyl-6-[2-phenylsulfanyl-3-(2-trimethylsilanyl-ethoxymethyl)-3H-imidazol-4-yl]-tetrahydro-[1,3]dioxolo[4,5-c]pyrrole 
• 188744-83-4 (1S)-1-(4-bromophenyl)-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 
• 258834-85-4 (1S)-1-[(N-tert-butoxycarbonylamino)methyl]phenyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-D-ribitol 
• 258834-83-2 (1S)-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-O-isopropylidene-1-{2,3-bis[di-(4-methoxybenzyl)amino]-5-pyridyl}-D-ribitol 
• 299917-12-7 (1S)-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1,4-imino-2,3-isopropylidene-1-C-{4-methoxy-5-N-(2-trimethylsilyl)ethoxymethylpyrrolo[3,2-d]pyrimidin-7-yl}-D-ribitol 
• 364046-19-5 1S-N-tert-butoxycarbonyl-5-O-tert-butyldimethylsilyl-1,4-dideoxy-1-C-[(4-methyoxypyrrolo[3,2-d]pyrimidin-9-N-(benzyloxomethyl)-7-yl)]-1,4-imino-2,3-O-isopropylidine-D-ribitol 
• 402477-37-6 (2S,3S,4R,5R)-tert-butyl 2-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 917595-31-4 (6aR,8S,9S,9aR)-tert-butyl 8-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro-[1,3,5,2,4]trioxadisilocino[7,6-b]pyrrole-7(8H)-carboxylate 
• 1163713-16-3 (6aR,8S,9R,9aR)-tert-butyl 8-(5-(benzyloxymethyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-9-hydroxy-2,2,4,4-tetraisopropyltetrahydro[1,3,5,2,4]trioxadisilocino[7,6-d]pyrrole-7(8H)-carboxylate 
• 402477-42-3 (2S,3S,4R,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 577978-31-5 (2S,3S,4R,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-hydroxy-4-((4-methoxybenzyl)oxy)-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 402477-45-6 (2S,3S,4R,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-4-hydroxy-3-((4-methoxybenzyl)oxy)-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 1163713-17-4 (2S,3S,4S,5R)-tert-butyl 2-(5-((benzyloxy)methyl)-4-methoxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-4-hydroxy-3-((4-methoxybenzyl)oxy)-5-((trityloxy)methyl)pyrrolidine-1-carboxylate 
• 1610426-17-9 (3aR,4R,6S,6aS)-tert-butyl 4-((benzyloxy)methyl)-6-((Z)-3-(tert-butoxy)-1-hydroxy-3-oxoprop-1-en-2-yl)-2,2-dimethyldihydro-3aH-[1,3]dioxolo[4,5-c]pyrrole-5(4H)-carboxylate 

Relevant articles and documents

8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases

The 8-aza-immucillins (8-aza-9-deazapurines linked from C9 to C1 of 1,4-dideoxy-1,4-iminoribitol) have been designed as transition-state analogues of the reactions catalyzed by purine nucleoside phosphorylase and nucleoside hydrolases. Syntheses of the 8-aza-immucillin analogues of inosine and adenosine are described. They are powerful inhibitors of the target enzymes with equilibrium dissociation constants as low as 42 pM.

ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES

Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral RNA polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration. Also disclosed are pharmaceutical compositions comprising one or more compounds mentioned above, or pharmaceutically acceptable salts thereof, as well as methods for preparing same. Also provided are methods for inhibiting viral RNA polymerase activity, viral replication, and treating viral infections.

Process for preparing 2-pyrrolidinyl-1H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside metabolism

A process of preparing a compound of the formula (I) wherein B is chosen from OH, NH2, NHR, H or halogen; D is chosen from OH, NH2, NHR, H halogen or SCH3; R is an optionally substituted alkyl, aralkyl or aryl group; and Z is selected from OH, hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted all, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof, which comprises reacting a compound of the formula (II) ?with an anion produced by abstraction of the bromine or iodine atom from a compound of formula (XIX), ?to form a compound of formula (XX) The compound of formula (XX) is N- and O-deprotected to obtain the compound of formula (I).